Under the terms of this licensing agreement, Sirion will have the rights to manufacture, sell and distribute norketotifen for ocular use either alone or in combination with other drugs.
Roger Vogel, chief medical officer of Sirion, said: “This agreement represents yet another significant milestone for Sirion. We are very excited about the medical and market potential of the norketotifen molecule.”